Sartorius acquires major stake in ALS Automated Lab Solutions

The life science group Sartorius is expanding its bio-analytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions GmbH. The laboratory technology company based in Jena, Germany, develops, manufactures and markets solutions for the automated analysis, selection and isolation of cells. With these solutions, ALS enables life science customers to significantly reduce time to result and cost in cell line development and antibody discovery. Other application areas are the development of cell and gene therapeutics as well as rare single cell molecular diagnostics in cancer and prenatal research. Sartorius is initially purchasing 62.5 per cent of the shares in ALS as of January 3, 2022. The remaining 37.5 per cent will be acquired in 2026. ALS currently employs around 30 people and is expected to generate sales in the high single-digit million-euro area in 2021, with a double-digit EBITDA margin.